GENERAL (Narrative) (Details) $ / shares in Units, $ in Thousands |
12 Months Ended | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aug. 01, 2023
$ / shares
|
May 08, 2023
CAD ($)
|
May 08, 2023
USD ($)
$ / shares
shares
|
Mar. 28, 2023
CAD ($)
|
Mar. 08, 2023 |
Feb. 13, 2023
CAD ($)
|
Apr. 06, 2022
CAD ($)
|
May 10, 2021
$ / shares
|
Dec. 31, 2023
CAD ($)
shares
|
Dec. 31, 2022
CAD ($)
shares
|
Dec. 31, 2021
CAD ($)
|
Dec. 31, 2020
CAD ($)
|
Feb. 28, 2023
shares
|
Nov. 07, 2022
CAD ($)
|
||||
| Disclosure of subsidiaries [line items] | |||||||||||||||||
| Number of shares issued | shares | 13,394,136 | 7,569,526 | 1,159,999 | ||||||||||||||
| Exercise price of warrants issued per common share | $ / shares | $ 7.2 | ||||||||||||||||
| Retained earnings | $ (249,145,000) | $ (239,574,000) | |||||||||||||||
| Cash and cash equivalents | 1,813,000 | 2,449,000 | $ 13,903,000 | $ 8,885,000 | $ 406,000 | ||||||||||||
| Outstanding indebtedness settled | 4,827,000 | 4,976,000 | 0 | ||||||||||||||
| Net loss for the year | (12,792,000) | $ (30,791,000) | (23,035,000) | [1] | |||||||||||||
| Closing bid price of the common shares | $ / shares | $ 1 | ||||||||||||||||
| Nasdaq Letter Requirements | The Notification Letter provided that the Company has until January 16, 2024, being 180 calendar days following receipt of such notice to regain compliance with the Minimum Share Price Listing Requirement for a minimum of 10 consecutive business days (See also see note 26) | ||||||||||||||||
| Tax on premiums, tax on insurance | 72,944,920 | 198,687,570 | |||||||||||||||
| Tax on premiums, arrears of interest | 1,533,750 | 36,248,620 | |||||||||||||||
| Tax on premiums, penalty on failure | $ 499,480 | $ 7,947,490 | |||||||||||||||
| Contingency, damages sought | 15,000,000 | ||||||||||||||||
| L5 Capital [Member] | |||||||||||||||||
| Disclosure of subsidiaries [line items] | |||||||||||||||||
| Par value per share | $ / shares | $ 1.25 | ||||||||||||||||
| Number of shares issued | shares | 492,492 | ||||||||||||||||
| Outstanding indebtedness settled | $ 838,776,000 | $ 615,615 | |||||||||||||||
| Description of unit | Each Unit consists of one Common Share of the Company and one Common Share purchase Warrant. Each Warrant entitles L5 Capital to purchase one additional Common Share at an exercise price of US$1.50 per Common Share for a period of 36 months from the date of issuance | Each Unit consists of one Common Share of the Company and one Common Share purchase Warrant. Each Warrant entitles L5 Capital to purchase one additional Common Share at an exercise price of US$1.50 per Common Share for a period of 36 months from the date of issuance | |||||||||||||||
| Sde Avraham Cultivation Facility [Member] | |||||||||||||||||
| Disclosure of subsidiaries [line items] | |||||||||||||||||
| Restructuring expenses | $ 4,383,000 | 617,000 | |||||||||||||||
| Workforce reduction description | The Company reduced its workforce in Israel across all functions (including executives) | ||||||||||||||||
| Panaxia Transaction [Member] | |||||||||||||||||
| Disclosure of subsidiaries [line items] | |||||||||||||||||
| Fifth installment value | $ 262,000 | ||||||||||||||||
| Compensation amount | $ 95,000 | ||||||||||||||||
| Trichome Financial Corp. (“Trichome”) [Member] | |||||||||||||||||
| Disclosure of subsidiaries [line items] | |||||||||||||||||
| Aggregate consideration | $ 3,375,000 | ||||||||||||||||
| Tjac And Certain Mym Subsidiaries [Member] | |||||||||||||||||
| Disclosure of subsidiaries [line items] | |||||||||||||||||
| Retained earnings | 249,145,000 | ||||||||||||||||
| Cash and cash equivalents | 1,813,000 | ||||||||||||||||
| Working capital of business acquisition | 8,543,000 | ||||||||||||||||
| Net cash used in operating activities | 8,075,000 | ||||||||||||||||
| Net loss for the year | $ 12,792,000 | ||||||||||||||||
| |||||||||||||||||